Publications (227) MIGUEL ARRABAL MARTÍN publications

2024

  1. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    OncoImmunology, Vol. 13, Núm. 1

  2. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  3. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 35, Núm. 2, pp. 159-182

  5. Efectividad de la estimulación del nervio tibial posterior en pacientes con vejiga hiperactiva resistentes al tratamiento médico

    Enfuro, Núm. 143, pp. 8-12

  6. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

    European Journal of Cancer, Vol. 199

  7. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000

  8. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

  9. Preliminary results of the external urinary sphincter Uroflex® on the quality of life of patients with male urinary incontinence after prostate surgery: tolerance, severity of incontinence, and quality of life

    International Urology and Nephrology

  10. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  11. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2023

  1. A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results

    Urolithiasis, Vol. 51, Núm. 1

  2. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 4, pp. 166-176

  3. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 10, pp. 7453-7459

  4. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  5. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  6. Beyond October, Beyond Pink: A Year-Round Revelation for Women’s Breast Health

    Journal of Women's Health, Vol. 32, Núm. 11, pp. 1143-1146

  7. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  8. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 41, Núm. 2, pp. 109.e1-109.e8

  9. Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer

    Bladder Cancer, Vol. 9, Núm. 2, pp. 159-166